<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - FOSPHENYTOIN SODIUM</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>FOSPHENYTOIN SODIUM</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#preTreatmentScreening" data-toggle="tab">Pre-treatment screening</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Status epilepticus</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 20 mg(PE)/kg, dose to be administered at a rate of 100&#8211;150 mg(PE)/minute, then 4&#8211;5 mg(PE)/kg daily in 1&#8211;2 divided doses, dose to be administered at a rate of 50&#8211;100 mg(PE)/minute, dose to be adjusted according to response and trough plasma-phenytoin concentration.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Consider 10&#8211;25% reduction in dose or infusion rate.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis or treatment of seizures associated with neurosurgery or head injury</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 10&#8211;15 mg(PE)/kg, intravenous infusion to be administered at a rate of 50&#8211;100 mg(PE)/minute, then 4&#8211;5 mg(PE)/kg daily in 1&#8211;2 divided doses, intravenous infusion to be administered at a rate of 50&#8211;100 mg(PE)/minute, dose to be adjusted according to response and trough plasma-phenytoin concentration.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Consider 10&#8211;25% reduction in dose or infusion rate.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Temporary substitution for oral phenytoin</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Intravenous infusion to be administered at a rate of 50&#8211;100 mg(PE)/minute, same dose and same dosing frequency as oral phenytoin therapy.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Consider 10&#8211;25% reduction in dose or infusion rate.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>Doses are expressed as phenytoin sodium equivalent (PE); fosphenytoin sodium 1.5&#8239;mg &#8801; phenytoin sodium 1&#8239;mg.</p>
            </section>
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Fosphenytoin is a pro-drug of phenytoin.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>Consider 10&#8211;25% reduction in dose or infusion rate (except initial dose for status epilepticus).</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Consider 10&#8211;25% reduction in dose or infusion rate (except initial dose for status epilepticus).</p>
            </section>
        
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li><xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref></li>
            <li>second-degree heart block</li>
            <li>sino-atrial block</li>
            <li>sinus bradycardia</li>
            <li>Stokes-Adams syndrome</li>
            <li>third-degree heart block</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Alterations in respiratory function, arrhythmias, asthenia, cardiovascular collapse, cardiovascular depression (particularly if injection too rapid), chills, CNS depression (particularly if injection too rapid), dry mouth, dysarthria, ecchymosis, euphoria, hypotension, incoordination, pruritus, respiratory arrest, taste disturbance, tinnitus, vasodilatation, visual disturbances,
              </p>
              <p>
                <strong>uncommon:</strong> Decreased reflexes, hypoacusis, hypoaesthesia, increased reflexes, muscle spasm, muscle weakness, pain, stupor,
              </p>
              <p>
                <strong>notKnown:</strong> Confusion, extrapyramidal disorder, hyperglycaemia, purple glove syndrome, tonic seizures, twitching,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>notKnown:</strong> bradycardia, heart block,
              </p>
        
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
                <p class="title">Important</p>
              <p>Intravenous infusion of fosphenytoin has been associated with severe cardiovascular reactions including asystole, ventricular fibrillation, and cardiac arrest. Hypotension, bradycardia, and heart block have also been reported. The following are recommended:</p><ul>
            <li>monitor heart rate, blood pressure, and respiratory function for duration of infusion;</li>
            <li>observe patient for at least 30 minutes after infusion;</li>
            <li>if hypotension occurs, reduce infusion rate or discontinue;</li>
            <li>reduce dose or infusion rate in elderly, and in renal or hepatic impairment.</li>
            </ul>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>For <i>intermittent intravenous infusion</i> (<i>Pro-Epanutin</i>
            <tm tmtype="reg"/>), give <i>in</i> Glucose 5% <i>or</i> Sodium chloride 0.9%; dilute to a concentration of 1.5&#8211;25&#8239;mg (phenytoin sodium equivalent (PE))/mL.</p>
            </section>
      </section>




      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Heart failure
          </li>
          <li>
            hypotension
          </li>
          <li>
            injection solutions alkaline (irritant to tissues)
          </li>
          <li>
            respiratory depression
          </li>
          <li>
            resuscitation facilities must be available
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Manufacturer recommends blood counts (but evidence of practical value uncertain).</p>
            </section>
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>ECG monitoring.</p>
            </section>
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Monitor heart rate, blood pressure, and respiratory function for duration of infusion.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Fosphenytoin sodium doses in BNF may differ from those in product literature.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Prescriptions for fosphenytoin sodium should state the dose in terms of phenytoin sodium equivalent (PE); fosphenytoin sodium 1.5&#8239;mg &#8801; phenytoin sodium 1&#8239;mg.</p>
            </section>
      </section>




      <section class="tab-pane" id="preTreatmentScreening">
        <h2>Pre-treatment screening</h2>

            <section class="preTreatmentScreening">
              <p>HLA-B* 1502 allele in individuals of Han Chinese or Thai origin&#8212;avoid unless essential (increased risk of Stevens-Johnson syndrome).</p>
            </section>
      </section>




      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

        
            <section class="crossSensitivity">
              <p>Cross-sensitivity reported with carbamazepine.</p>
            </section>
      </section>

      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of FOSPHENYTOIN SODIUM</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP77327"><a href="../medicinalForm/PHP77327.html" data-target="#PHP77327" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
